高级检索
当前位置: 首页 > 详情页

Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Neurology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China [2]Department of Neurology, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China [3]Department of Infectious Diseases, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China [4]School of Clinical Medicine, North China University of Science and Technology, Tangshan, Hebei, China [5]Department of Neurology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China [6]Department of Reproductive Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
出处:
ISSN:

关键词: Non-small cell lung cancer Leptomeningeal metastasis Cerebrospinal fluid circulating tumour DNA Targeted therapy

摘要:
Non-small cell lung cancer with leptomeningeal metastasis (NSCLC-LM) is emerging as a new management challenge for oncologists and is associated with poor prognosis. This study aimed to investigate the molecular characteristics and prognostic factors of NSCLC-LM.This retrospective study included 97 patients with NSCLC-LM between January 2015 and October 2021. Progression-free survival (PFS) and overall survival (OS) were evaluated. Gene mutations were detected by next-generation sequencing (NGS).The median PFS and OS were 8.4 (95 % confidence interval [CI]: 4.839-11.901) and 14.0 (95 % CI: 9.254-18.746) months, respectively. Sixty-seven patients harboured epidermal growth factor receptor-mutated (EGFRm): L858R (34), 19del (29), T790M (13), and G719C with L861Q (1). Other mutations included ALK (5), ROS1 (3), KRAS (1), TP53 (14), MET amplification (6). The detection rate and types of circulating tumour DNA (ctDNA) in the cerebrospinal fluid (CSF) samples were higher than the paired plasma samples. Patients with EGFR mutations had a longer median OS than those without mutations (19.0 vs. 13.0 months, P = 0.015). Patients with gene mutations had shorter median OS than those without mutations, such as ALK (11.8 vs. 19.9 months, P = 0.014), ROS1 (12.7 vs. 19.8 months, P = 0.014), KRAS (4.0 vs. 19.0 months, P = 0.005), TP53 (15.0 vs. 19.0 months, P = 0.014), and MET amplification (6.0 vs. 19.0 months, P = 0.003). Multivariate analysis indicated that MET amplification was an independent predictor of poor survival. Along with Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥ 3, LM accompanied with brain parenchymal metastasis (BPM), extracranial disease, and seizures were independent predictors of poor survival, whereas intrathecal chemotherapy, and third-generation EGFR-TKIs were independent predictors of favorable survival.CSF ctDNA detected using NGS had a high sensitivity for NSCLC-LM, showing high potential in detecting driver and drug-resistant gene mutations. Genomic profiles, combined with clinically relevant prognostic factors, will guide individualised treatments and improve the outcomes of NSCLC-LM patients.Copyright © 2023. Published by Elsevier B.V.

基金:

基金编号: 2021

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2023]版:
大类 | 4 区 医学
小类 | 4 区 临床神经病学 4 区 外科
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 临床神经病学 4 区 外科
JCR分区:
出版当年[2023]版:
Q2 SURGERY Q3 CLINICAL NEUROLOGY
最新[2023]版:
Q2 SURGERY Q3 CLINICAL NEUROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Department of Neurology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China [2]Department of Neurology, North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China
通讯作者:
通讯机构: [1]Department of Neurology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China [*1]Department of Neurology, The Fourth Hospital of Hebei Medical University, No. 12, Health Road, Shijiazhuang, Hebei 050000, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号